 AUSTIN, Texas, Sept. 17, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a leader in cell-free DNA testing, today announced new data being presented by the company and its collaborators on the use of the Signatera personalized molecular residual disease MRD technology at the 2021 European Society for Medical Oncology ESMO Congress, taking place September 1621, 2021. 